Global repeated-measures ANOVA incorporating all the cell-development variables (treatment, age, region, sex, four measures) indicated a main treatment effect for DZN (p < 0.03), reflecting a significant overall difference for the low-dose DZN group compared with either controls (p < 0.03) or the high-dose DZN group (p < 0.003).
The main measure was weight loss.
The main measures consist of screening for markers indicating chronic HBV infection (HBsAg) or HBV infection in the distant past (antibodies to the HBV core antigen) before initiating biological therapies, vaccinating marker-negative patients, and considering close follow-up or antiviral treatment before immunosuppressive treatment initiation or in the event of HBV reactivation.
It contains 2 main measures.
Main measured outcomes included IVF outcomes.
Main outcome measures: Respondents indicated how often they initiated discussion of complementary therapies, their comfort level discussing this subject, and the perceived impact on the patient professional relationship.
Main Outcome Measure: Repositioning accuracy, indicating the difference in degrees between the criterion and matching positions.
MRT: mean reaction time in milliseconds; SD-RT: within-subject variability in RTs in milliseconds; CV: coefficient of variation (SD-RT/MRT) Repeated measures ANOVA indicated a main effect of time on task for MRT in the CPT-OX [F 1, 38) = 7.60, p < 0.01, d = 0.90] with no group by time interaction [F 1, 38) = 0.92, p = 0.34].
Repeated measures ANOVA indicated a significant main effect for FVII C AUC, F 3, 144) = 5.08, ε =.807, P =.005.
Repeated measures ANOVA indicated no significant main effect for FVIII C AUC, F 3, 117) =.933, ε =.632, P =.394.
